



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 9/00	A1	(11) International Publication Number: WO 97/20918 (43) International Publication Date: 12 June 1997 (12.06.97)															
(21) International Application Number: PCT/US96/19457 (22) International Filing Date: 6 December 1996 (06.12.96) (30) Priority Data: <table border="0"><tr><td>60/008,316</td><td>7 December 1995 (07.12.95)</td><td>US</td></tr><tr><td>60/008,317</td><td>7 December 1995 (07.12.95)</td><td>US</td></tr><tr><td>60/008,311</td><td>7 December 1995 (07.12.95)</td><td>US</td></tr><tr><td>08/651,568</td><td>22 May 1996 (22.05.96)</td><td>US</td></tr><tr><td>08/692,002</td><td>2 August 1996 (02.08.96)</td><td>US</td></tr></table> (71) Applicant: RECOMBINANT BIOCATALYSIS, INC. [US/US]; 505 Coast Boulevard South, La Jolla, CA 92037 (US). (72) Inventor: SHORT, Jay, M.; 320 Delage Drive, Encinitas, CA 92024 (US). (74) Agents: HERRON, Charles, J. et al.; Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein, 6 Becker Farm Road, Roseland, NJ 07068 (US).		60/008,316	7 December 1995 (07.12.95)	US	60/008,317	7 December 1995 (07.12.95)	US	60/008,311	7 December 1995 (07.12.95)	US	08/651,568	22 May 1996 (22.05.96)	US	08/692,002	2 August 1996 (02.08.96)	US	(81) Designated States: AU, CA, IL, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
60/008,316	7 December 1995 (07.12.95)	US															
60/008,317	7 December 1995 (07.12.95)	US															
60/008,311	7 December 1995 (07.12.95)	US															
08/651,568	22 May 1996 (22.05.96)	US															
08/692,002	2 August 1996 (02.08.96)	US															
(54) Title: METHOD OF SCREENING FOR ENZYME ACTIVITY (57) Abstract Disclosed are processes to identify desired enzymatic activity from a pool of DNA collected from one or more organisms or a DNA subjected to random directed mutagenesis. The methods involve the generation of DNA library in a host cell and screening for the desired activity. The process can be applied to develop thermally stable proteins having improved enzymatic activity at lower temperature.																	

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

METHOD OF SCREENING FOR ENZYME ACTIVITY

This application is a continuation-in-part of U.S. application serial no. 08/692,002 filed on August 2, 1996 (copending) which is a continuation-in-part of U.S. provisional application no. 60/008,317 which was filed on December 7, 1995 (copending); a continuation-in-part of U.S. application serial no. 08/651,568 filed on May 22, 1996 (copending) which is a continuation-in-part of U.S. provisional application no. 60/008,316 which was filed on December 7, 1995 (copending); and a continuation-in-part of U.S. provisional application no. 60/008,311 which was filed on December 7, 1995 (copending).

The present invention relates to the production and screening of expression libraries for enzyme activity and, more particularly, to obtaining selected DNA from DNA of a microorganism and to screening of an expression library for enzyme activity which is produced from selected DNA, to the directed mutagenesis of DNA and screening of clones containing the mutagenized DNA for resultant specified protein, particularly enzyme, activity(ies) of interest, and to thermostable enzymes, more particularly, the present invention relates to thermostable enzymes which are stable at high temperature and which have improved activity at lower temperatures.

SUMMARY OF THE INVENTION

Industry has recognized the need for new enzymes for a wide variety of industrial applications. As a result, a variety of microorganisms have been screened to ascertain whether such microorganisms have a desired enzyme activity. If such microorganisms do have the desired enzyme activity, the enzyme is then recovered from them. The present invention provides a novel approach for obtaining enzymes for further use, for example, for a wide variety of industrial applications, for medical applications, for packaging into kits for use as research reagents, etc.

Thus, in accordance with the present invention, recombinant enzymes are generated from microorganisms and are classified by various enzyme characteristics.

More particularly, one aspect of the present invention provides a process for identifying clones having a specified enzyme activity, which process comprises:

screening for said specified enzyme activity in a library of clones prepared by

(i) selectively isolating target DNA, from DNA derived from at least one microorganism, by use of at least one probe DNA comprising at least a portion of a DNA sequence encoding an enzyme having the specified enzyme activity; and

(ii) transforming a host with isolated target DNA to produce a library of clones which are screened, preferably for the specified enzyme activity, using an activity library screening or nucleic acid library screening protocol.

In a preferred embodiment of this aspect, DNA obtained from at least one microorganism is selected by recovering from the DNA, DNA which specifically binds, such as by hybridization, to a probe DNA sequence. The

DNA obtained from the microorganism or microorganisms can be genomic DNA or genomic gene library DNA. One could even use DNA prepared for vector ligation, for instance. The probe may be directly or indirectly bound to a solid phase by which it is separated from the DNA which is not hybridized or otherwise specifically bound to the probe. The process can also include releasing DNA from said probe after recovering said hybridized or otherwise bound DNA and amplifying the DNA so released.

The invention also provides for screening of the expression libraries for gene cluster protein product(s) and, more particularly, to obtaining selected gene clusters from DNA of a prokaryote or eukaryote and to screening of an expression library for a desired activity of a protein of related activity(ies) of a family of proteins which results from expression of the selected gene cluster DNA of interest.

More particularly, one embodiment of this aspect provides a process for identifying clones having a specified protein(s) activity, which process comprises screening for said specified enzyme activity in the library of clones prepared by (i) selectively isolating target gene cluster DNA, from DNA derived from at least one organism, by use of at least one probe polynucleotide comprising at least a portion of a polynucleotide sequence complementary to a DNA sequence encoding the protein(s) having the specified activity of interest; and (ii) transforming a host with isolated target gene cluster DNA to produce a library of such clones which are screened for the specified activity of interest. For example, if one is using DNA in a lambda vector one could package the DNA and infect cells via this route.

In a particular embodiment of this aspect, gene cluster DNA obtained from the genomic DNA of the organism(s) is selected by recovering from the DNA, DNA

which specifically binds, such as by hybridization, to a probe DNA sequence. The polynucleotide probe may be directly or indirectly bound to a solid phase by which it is separated from the DNA which is not hybridized or otherwise specifically bound to the probe. This embodiment of this aspect of the process of the invention can also include releasing bound DNA from said probe after recovering said hybridized or otherwise bound DNA and amplifying the DNA so released.

Another aspect of the invention provides a process for obtaining an enzyme having a specified enzyme activity derived from a heterogeneous DNA population, which process comprises screening, for the specified enzyme activity, a library of clones containing DNA from the heterogeneous DNA population which have been exposed to directed mutagenesis towards production of the specified enzyme activity.

Another aspect of the invention provides a process for obtaining an enzyme having a specified enzyme activity, which process comprises: screening, for the specified enzyme activity, a library of clones containing DNA from a pool of DNA populations which have been exposed to directed mutagenesis in an attempt to produce in the library of clones DNA encoding an enzyme having one or more desired characteristics, which can be the same or different from the specified enzyme activity. In a preferred embodiment, the DNA pool which is subjected to directed mutagenesis is a pool of DNA which has been selected to encode enzymes having at least one enzyme characteristic, in particular at least one common enzyme activity.

Also provided is a process for obtaining a protein having a specified activity derived from a heterogeneous population of gene clusters by screening, for the specified protein activity, a library of clones

containing gene clusters from the heterogeneous gene cluster population which have been exposed to directed mutagenesis towards production of specified protein activities of interest.

Also provided is a process of obtaining a gene cluster protein product having a specified activity, by screening, for the specified protein activity, a library of clones containing gene clusters from a pool of gene cluster populations which have been exposed to directed mutagenesis to produce in the library of clones gene clusters encoding proteins having one or more desired characteristics, which can be the same or different from the specified protein activity. Preferably, the pool of gene clusters which is subjected to directed mutagenesis is one which has been selected to encode proteins having enzymatic activity in the synthesis of at least one therapeutic, prophylactic or physiological regulatory activity.

The process of either of these aspects can further comprise, prior to the directed mutagenesis, selectively recovering from the heterogeneous population of gene clusters, gene clusters which comprise polycistronic sequences coding for proteins having at least one common physical, chemical or functional characteristic which can be the same or different from the activity observed prior to directed mutagenesis. Preferably, recovering the gene cluster preparation comprises contacting the gene cluster population with a specific binding partner, such as a solid phase-bound hybridization probe, for at least a portion of the gene cluster of interest. The common characteristic of the resultant protein(s) can be classes of the types of activity specified above, i.e., such as a series of enzymes related as parts of a common synthesis pathway or proteins capable of hormonal, signal transduction or inhibition of metabolic pathways or their functions in pathogens and the like. The gene cluster

DNA is recovered from clones containing such gene cluster DNA from the heterogeneous gene cluster population which exhibit the activity of interest. Preferably, the directed mutagenesis is site-specific directed mutagenesis. This process can further include a step of pre-screening the library of clones for an activity, which can be the same or different from the specified activity of interest, prior to exposing them to directed mutagenesis. This activity can result, for example, from the expression of a protein or related family of proteins of interest.

The process of any of these aspects can further comprise, prior to said directed mutagenesis, selectively recovering from the heterogeneous DNA population DNA which comprises DNA sequences coding for enzymes having at least one common characteristic, which can be the same or different from the specified enzyme activity. Preferably, recovering the DNA preparation comprises contacting the DNA population with a specific binding partner, such as a solid phase bound hybridization probe, for at least a portion of the coding sequences. The common characteristic can be, for example, a class of enzyme activity, such as hydrolase activity. DNA is recovered from clones containing DNA from the heterogeneous DNA population which exhibit the class of enzyme activity. Preferably, the directed mutagenesis is site-specific directed mutagenesis. The process of this aspect can further include a step of prescreening the library of clones for an activity, which can be the same or different from the specified enzyme activity, prior to exposing them to directed mutagenesis. This activity can result, for example, from the expression of a protein of interest.

The heterogeneous DNA population from which the DNA library is derived is a complex mixture of DNA, such as is obtained, for example, from an environmental sample.

Such samples can contain unculturable, uncultured or cultured multiple or single organisms. These environmental samples can be obtained from, for example, Arctic and Antarctic ice, water or permafrost sources, materials of volcanic origin, materials from soil or plant sources in tropical areas, etc. A variety of known techniques can be applied to enrich the environmental sample for organisms of interest, including differential culturing, sedimentation gradient, affinity matrices, capillary electrophoresis, optical tweezers and fluorescence activated cell sorting. The samples can also be cultures of a single organism.

Thermostable enzymes are enzymes that function at greater than 60°C. Thermostable enzymes are utilized in both industry and biomedical research in assays where certain steps of the assay are performed at significantly increased temperatures. Thermostable enzymes may be obtained from thermophilic organisms found in hot springs, volcanic origin, tropical areas etc. Examples of such organisms, for instance, include prokaryotic microorganisms, such as eubacteria and archaeobacteria (Bronneomerier, K. and Staudenbauer, W. L., D.R. Woods (ed), the Clostridia and Biotechnology, Butterworth Publishers, Stoneham, M.A. (1993), among other organisms.

Thermostable enzymes exhibit greater storage life capacity and organic solvent resistance, as compared to their mesophilic counterparts.

There are applications in industry and in research for thermostable enzymes which exhibit enzyme activity at a desired minimum temperature. An example of this occurs in molecular diagnostics wherein reporter molecules must survive long term storage at room temperature or higher or they need to function in unusual environments, and the assays which employ them are performed at room

temperature where the activity of thermostable enzymes is generally very low.

Thus, another embodiment of the invention provides a process for providing a thermostable enzyme having improved enzyme activities at lower temperatures, said enzyme being a member selected from the group consisting of an enzyme or a polynucleotide encoding said enzyme comprising:

- (a) subjecting to mutagenesis at least one enzyme which is stable at a temperature of at least 60°C; and
- (b) screening mutants produced in (a) for a mutated enzyme or polynucleotide encoding a mutated enzyme, which mutated enzyme is stable at a temperature of at least 60°C and which has an enzyme activity at a temperature of less than 50°C and which has activity greater than the enzyme of step (a).

These and other aspects of the present invention will be apparent to those skilled in the art from the teachings herein.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B. Figure 1A is a photograph of an agarose gel containing standards and samples a-f described in Example 2. Samples c-f represent DNA recovered from a genomic DNA library using two specific DNA probes and amplified using gene specific primers, as described in Example 2. Figure 1B is also a photograph of an agarose gel containing standards and samples a-f described in Example 2. Samples c-f represent DNA recovered from a genomic DNA library using two specific DNA probes and amplified using vector specific primers, as described in Example 2.

Figure 2 is a photograph of four colony hybridization plates. Plates A and B showed positive clones i.e., colonies which contained DNA prepared in

accordance with the present invention, also contained probe sequence. Plates C and D were controls and showed no positive clones.

Figure 3 illustrates the full length DNA sequence and corresponding deduced amino acid sequence of *Thermococcus* 9N2 Beta-glycosidase.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The terms "derived" or "isolated" means that material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide separated from some or all of the coexisting materials in the natural system, is isolated.

The term "error-prone PCR" refers to a process for performing PCR under conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product. Leung, D.W., et al., *Technique*, 1:11-15 (1989) and Caldwell, R.C. & Joyce G.F., *PCR Methods Applic.*, 2:28-33 (1992).

The term "oligonucleotide directed mutagenesis" refers to a process which allows for the generation of site-specific mutations in any cloned DNA segment of interest. Reidhaar-Olson, J.F. & Sauer, R.T., et al., *Science*, 241:53-57 (1988).

The term "assembly PCR" refers to a process which involves the assembly of a PCR product from a mixture of small DNA fragments. A large number of different PCR reactions occur in parallel in the same vial, with the

products of one reaction priming the products of another reaction.

The term "sexual PCR mutagenesis" refers to forced homologous recombination between DNA molecules of different but highly related DNA sequence *in vitro*, caused by random fragmentation of the DNA molecule based on sequence homology, followed by fixation of the crossover by primer extension in a PCR reaction. Stemmer, W.P., PNAS, USA, 91:10747-10751 (1994).

The term "*in vivo* mutagenesis" refers to a process of generating random mutations in any cloned DNA of interest which involves the propagation of the DNA in a strain of *E. coli* that carries mutations in one or more of the DNA repair pathways. These "mutator" strains have a higher random mutation rate than that of a wild-type parent. Propagating the DNA in one of these strains will eventually generate random mutations within the DNA.

The term "cassette mutagenesis" refers to any process for replacing a small region of a double stranded DNA molecule with a synthetic oligonucleotide "cassette" that differs from the native sequence. The oligonucleotide often contains completely and/or partially randomized native sequence.

The term "recursive ensemble mutagenesis" refers to an algorithm for protein engineering (protein mutagenesis) developed to produce diverse populations of phenotypically related mutants whose members differ in amino acid sequence. This method uses a feedback mechanism to control successive rounds of combinatorial cassette mutagenesis. Arkin, A.P. and Youvan, D.C., PNAS, USA, 89:7811-7815 (1992).

The term "exponential ensemble mutagenesis" refers to a process for generating combinatorial libraries with

a high percentage of unique and functional mutants, wherein small groups of residues are randomized in parallel to identify, at each altered position, amino acids which lead to functional proteins, Delegrave, S. and Youvan, D.C., Biotechnology Research, 11:1548-1552 (1993); and random and site-directed mutagenesis, Arnold, F.H., Current Opinion in Biotechnology, 4:450-455 (1993). All of the references mentioned above are hereby incorporated by reference in their entirety.

As described with respect to one of the above aspects, the invention provides a process for enzyme activity screening of clones containing selected DNA derived from a microorganism which process comprises:

screening a library for specified enzyme activity, said library including a plurality of clones, said clones having been prepared by recovering from DNA of a microorganism selected DNA, which DNA is selected by hybridization to at least one DNA sequence which is all or a portion of a DNA sequence encoding an enzyme having the specified activity; and

transforming a host with the selected DNA to produce clones which are screened for the specified enzyme activity.

In one embodiment, a DNA library derived from a microorganism is subjected to a selection procedure to select therefrom DNA which hybridizes to one or more probe DNA sequences which is all or a portion of a DNA sequence encoding an enzyme having the specified enzyme activity by:

(a) rendering the double-stranded DNA population into a single-stranded DNA population;

(b) contacting the single-stranded DNA population of (a) with the DNA probe bound to a ligand under conditions permissive of hybridization so as to produce a double-stranded complex of probe and members of the DNA population which hybridize thereto;

(c) contacting the double-stranded complex of (b) with a solid phase specific binding partner for said ligand so as to produce a solid phase complex;

(d) separating the solid phase complex from the single-stranded DNA population of (b);

(e) releasing from the probe the members of the population which had bound to the solid phase bound probe;

(f) forming double-stranded DNA from the members of the population of (e);

(g) introducing the double-stranded DNA of (f) into a suitable host to form a library containing a plurality of clones containing the selected DNA; and

(h) screening the library for the specified enzyme activity.

In another embodiment, a DNA library derived from a microorganism is subjected to a selection procedure to select therefrom double-stranded DNA which hybridizes to one or more probe DNA sequences which is all or a portion of a DNA sequence encoding an enzyme having the specified enzyme activity by:

(a) contacting the double-stranded DNA population with the DNA probe bound to a ligand under conditions permissive of hybridization so as to produce a complex of probe and members of the DNA population which hybridize thereto;

(b) contacting the complex of (a) with a solid phase specific binding partner for said ligand so as to produce a solid phase complex;

(c) separating the solid phase complex from the unbound DNA population of (b);

(d) releasing from the probe the members of the population which had bound to the solid phase bound probe;

(e) introducing the double-stranded DNA of (d) into a suitable host to form a library containing a plurality of clones containing the selected DNA; and

(f) screening the library for the specified enzyme activity.

In another aspect, the process includes a preselection to recover DNA including signal or secretion sequences. In this manner it is possible to select from the DNA population by hybridization as hereinabove described only DNA which includes a signal or secretion sequence. The following paragraphs describe the protocol for this embodiment of the invention, the nature and function of secretion signal sequences in general and a specific exemplary application of such sequences to an assay or selection process.

Another particularly preferred embodiment of this aspect further comprises, after (a) but before (a) above, the steps of:

(i). contacting the double-stranded DNA population of (a) with a ligand-bound oligonucleotide probe that is complementary to a secretion signal sequence unique to a given class of proteins under conditions permissive of hybridization to form a double-stranded complex;

(ii). contacting the complex of (a i) with a solid phase specific binding partner for said ligand so as to produce a solid phase complex;

(iii) separating the solid phase complex from the unbound DNA population;

(iv) releasing the members of the population which had bound to said solid phase bound probe; and

(v) separating the solid phase bound probe from the members of the population which had bound thereto.

The DNA which has been selected and isolated to include a signal sequence is then subjected to the selection procedure hereinabove described to select and isolate therefrom DNA which binds to one or more probe DNA sequences derived from DNA encoding an enzyme(s) having the specified enzyme activity.

The pathways by which proteins are sorted and transported to their proper cellular location are often referred to as protein targeting pathways. One of the most important elements in all of these targeting systems is a short amino acid sequence at the amino terminus of a newly synthesized polypeptide called the signal sequence. This signal sequence directs a protein to its appropriate location in the cell and is removed during transport or when the protein reaches its final destination. Most lysosomal, membrane, or secreted proteins have an amino-terminal signal sequence that marks them for translocation into the lumen of the endoplasmic reticulum. More than 100 signal sequences for proteins in this group have been determined. The sequences vary in length from 13 to 36 amino acid residues.

A *phoA* expression vector, termed pMG, which, like TaphoA, is useful in identifying genes encoding membrane-spanning sequences or signal peptides. Giladi et al., J. Bacteriol., 175(13):4129-4136, 1993. This cloning system has been modified to facilitate the distinction of outer membrane and periplasmic alkaline phosphatase (AP) fusion proteins from inner membrane AP fusion proteins by transforming pMG recombinants into *E. coli* KS330, the strain utilized in the "blue halo" assay first described by Strauch and Beckwith, Proc. Nat. Acad. Sci. USA, 85:1576-1580, 1988. The pMG/KS330r cloning and screening approach can identify genes encoding proteins with cleavable signal peptides and therefore can serve as a first step in the identification of genes encoding polypeptides of interest.

Another embodiment of the invention provides a process for obtaining an enzyme having a specified enzyme activity, derived from a heterogeneous DNA population by screening, for the specified enzyme activity, a library of clones containing DNA from the heterogeneous DNA population which have been exposed to directed

mutagenesis towards production of the specified enzyme activity. The process can further comprise, prior to said directed mutagenesis, selectively recovering from the heterogeneous DNA population DNA which comprises DNA sequences coding for a common characteristic, which can be the same or different from the specified enzyme activity. The common characteristic can be, for example, a class of enzyme activity. This involves recovering DNA from clones containing DNA from the heterogeneous DNA population which exhibit the class of enzyme activity.

In this embodiment, recovering the DNA preparation preferably is done by contacting the DNA population with a specific binding partner, such as a solid phase bound hybridization probe, for at least a portion of the coding sequences.

The process of this embodiment can further comprise prescreening said library of clones for an activity, which can be the same or different from the specified enzyme activity, prior to exposing them to directed mutagenesis. The prescreening of said clones can be, for example, for the expression of a protein of interest.

Another embodiment of the invention provides a process for obtaining an enzyme having a specified enzyme activity, which process comprises screening, for the specified enzyme activity, a library of clones containing DNA from a pool of DNA populations which have been exposed to directed mutagenesis, which can be site-specific, in an attempt to produce in the library of clones DNA encoding an enzyme having one or more desired characteristics which can be the same or different from the specified enzyme activity. The process of this embodiment can further include, prior to said directed mutagenesis, selectively recovering from the heterogeneous DNA population DNA which comprises DNA sequences coding for at least one common enzyme

characteristic, which can be the same or different from the specified enzyme activity.

In this embodiment, recovering the DNA preparation can comprise contacting the DNA population with a specific binding partner for at least a portion of the coding sequences. The specific binding partner is a solid phase bound hybridization probe. DNA is recovered from clones containing DNA from the heterogeneous DNA population which exhibit the class of enzyme activity.

Applicant has found that it is possible to provide thermostable enzymes which have improved activity at lower temperatures. More particularly, Applicant has found that the activity of thermophilic enzymes can be improved at lower temperatures while maintaining the temperature stability of such enzymes. Further, it has been found that there can be obtained a thermostable enzyme with improved activity at lower temperature by subjecting to mutagenesis a thermostable enzyme or polynucleotide encoding such thermostable enzyme followed by a screening of the resulting mutants to identify a mutated enzyme or a mutated polynucleotide encoding a mutated enzyme, which mutated enzyme retains thermostability and which has an enzyme activity at lower temperatures which is at least two (2) times greater than a corresponding non-mutated enzyme.

The thermostable enzymes and mutated thermostable enzymes are stable at temperatures up to 60°C and preferably are stable at temperatures of up to 70°C and more preferably at temperatures up to 95°C and higher.

Increased activity of mutated thermostable enzymes at lower temperatures is meant to encompass activities which are at least two-fold, preferably at least four-fold, and more preferably at least ten-fold greater than that of the corresponding wild-type enzyme.

Increased enzyme activity at lower temperatures means that enzyme activity is increased at a temperature below 50°C, preferably below 40°C and more preferably below 30°C. Thus, in comparing enzyme activity at a lower temperature between the mutated and non-mutated enzyme, the enzyme activity of the mutated enzyme at defined lower temperatures is at least 2 times greater than the enzyme activity of the corresponding non-mutated enzyme.

Thus, lower temperatures and lower temperature ranges include temperatures which are at least 5°C less than the temperature at which thermostable enzymes are stable, which includes temperatures below 55°C, 50°C, 45°C, 40°C, 35°C, 30°C, 25°C and 20°C, with below 50°C being preferred, and below 40 being more preferred, and below 30°C (or approximately room temperature) being most preferred.

In accordance with this aspect of the invention, the lower temperature or lower temperature range at which a greater enzyme activity is desired is determined and a thermostable enzyme(s), or polynucleotide encoding such enzyme(s), are subjected to mutagenesis and the resulting mutants are screened to determine mutated enzymes (or polynucleotide encoding mutated enzymes) which retain thermostability and which have a minimum desired increase in enzyme activity at the desired temperature or temperature range.

Thermostable enzymes are enzymes which have activity, i.e. are not degraded, at temperatures above 60°C. Thermostable enzymes also have increased storage life, and high resistance to organic solvents.

Thermostable enzymes may be isolated from thermophilic organisms such as those which are found in elevated temperatures such as in hot springs, volcanic

areas and tropical areas. Examples of thermophilic organisms are prokaryotic organisms for example, thermophilic bacteria such as eubacteria and archaeobacteria.

The DNA from these thermostable organisms can then be isolated by available techniques that are described in the literature. The IsoQuick[®] nucleic acid extraction kit (MicroProbe Corporation) is suitable for this purpose.

Alternatively, enzymes not known to have thermostable properties can be screened for such properties by inserting the DNA encoding the enzyme in an expression vector and transforming a suitable host as hereinafter described, such that the enzyme may be expressed and screened for positive thermostable activity.

The isolated DNA encoding a thermostable enzyme is subjected to mutagenesis techniques, with the preferred type of mutagenesis techniques being set forth herein.

As can be seen from the above-defined mutagenesis techniques, the DNA encoding an enzyme having the desired activity may be subject to mutagenesis alone, i.e. as naked DNA, or the DNA may be subjected to mutagenesis after insertion into an appropriate vector as described herein. These techniques are referred to as *in vitro* mutagenesis.

Alternatively, *in vivo* mutagenesis may be performed wherein the DNA is subjected to mutagenesis while it is within a cell or living organism. A preferred example of this technique utilizes the XL1 Red Strain of *E. coli* (Stratagene, Inc.) which has its DNA repair genes, *MutH*, *MutL* and *MutS*, deleted such that many different mutations occur in a short time. Up to 10,000 mutations may take place within a 30 hour time span such that an entire

mutated DNA library may be prepared from mutated DNA by procedures known in the art.

After an appropriate amount of time to allow mutations to take place, the mutated DNA is excised from the host cell in the case of in vivo mutagenesis and inserted in another appropriate vector and used to transform a non-mutator host, for example, XL1 Blue strain of *E. coli* after which a mutated DNA library is prepared. In the case of in vitro mutagenesis, if the mutated DNA has previously been inserted in an appropriate expression vector, said vector is then used directly to transform an appropriate non-mutator host for the preparation of a mutated DNA library, if the mutagenized DNA is not in an appropriate expression vector.

A library is prepared for screening by transforming a suitable organism. Hosts, particularly those specifically identified herein as preferred, are transformed by artificial introduction of the vectors containing the mutated DNA by inoculation under conditions conducive for such transformation.

The resultant libraries of transformed clones are then screened for clones which display activity for the enzyme of interest in a phenotypic assay for enzyme activity.

For example, having prepared a multiplicity of clones from DNA mutagenized by one of the techniques described above, such clones are screened for the specific enzyme activity of interest.

For example, the clones containing the mutated DNA are now subject to screening procedures to determine their activity within both higher temperatures and within the desired lower temperature range to identify mutants

which have the desired increase in activity within the lower temperature range when compared to the corresponding wild-type thermostable enzyme which is non-mutated.

Positively identified clones, i.e. those which contain mutated DNA sequences which express thermostable enzymes which are thermostable and yet have an increased activity at least two times than the corresponding wild-type enzyme at temperatures within the lower temperature range, are isolated and sequenced to identify the DNA sequence. As an example, phosphatase activity at the desired lower temperature ranges may be identified by exposing the clones, and thus the thermostable enzyme and testing its ability to cleave an appropriate substrate.

In Example 7 phosphatase and β -galactosidase activity are measured by comparing the wild-type enzymes to the enzymes subjected to mutagenesis. As can be seen from the results reported there, mutagenesis of a wild-type phosphatase and β -galactosidase thermophilic enzyme produce mutated enzymes which were 3 and 2.5 times more active, respectively, at lower temperatures than the corresponding wild-type enzymes within the lower temperature range of room temperature.

In the case of protein engineering, after subjecting a thermophilic enzyme to mutagenesis, the mutagenized enzyme is screened for the desired activity namely, increased activity at lower temperatures while maintaining activity at the higher temperatures. Any of the known techniques for protein mutagenesis may be employed, with particularly preferred mutagenesis techniques being those discussed above.

The DNA derived from a microorganism(s) is preferably inserted into an appropriate vector (generally a vector containing suitable regulatory sequences for

effecting expression) prior to subjecting such DNA to a selection procedure to select and isolate therefrom DNA which hybridizes to DNA derived from DNA encoding an enzyme(s) having the specified enzyme activity.

The microorganisms from which the libraries may be prepared include prokaryotic microorganisms, such as Eubacteria and Archaeobacteria, and lower eukaryotic microorganisms such as fungi, some algae and protozoa. The microorganisms may be cultured microorganisms or uncultured microorganisms obtained from environmental samples and such microorganisms may be extremophiles, such as thermophiles, hyperthermophiles, psychrophiles, psychrotrophs, etc.

As indicated above, the library may be produced from environmental samples in which case DNA may be recovered without culturing of an organism or the DNA may be recovered from a cultured organism.

Sources of microorganism DNA as a starting material library from which target DNA is obtained are particularly contemplated to include environmental samples, such as microbial samples obtained from Arctic and Antarctic ice, water or permafrost sources, materials of volcanic origin, materials from soil or plant sources in tropical areas, etc. Thus, for example, DNA may be recovered from either a culturable or non-culturable organism and employed to produce an appropriate recombinant expression library for subsequent determination of enzyme activity.

Bacteria and many eukaryotes have a coordinated mechanism for regulating genes whose products are involved in related processes. The genes are clustered, in structures referred to as "gene clusters," on a single chromosome and are transcribed together under the control of a single regulatory sequence, including a single

promoter which initiates transcription of the entire cluster. The gene cluster, the promoter, and additional sequences that function in regulation altogether are referred to as an "operon" and can include up to 20 or more genes, usually from 2 to 6 genes. Thus, a gene cluster is a group of adjacent genes that are either identical or related, usually as to their function.

Some gene families consist of identical members. Clustering is a prerequisite for maintaining identity between genes, although clustered genes are not necessarily identical. Gene clusters range from extremes where a duplication is generated to adjacent related genes to cases where hundreds of identical genes lie in a tandem array. Sometimes no significance is discernable in a repetition of a particular gene. A principal example of this is the expressed duplicate insulin genes in some species, whereas a single insulin gene is adequate in other mammalian species.

It is important to further research gene clusters and the extent to which the full length of the cluster is necessary for the expression of the proteins resulting therefrom. Further, gene clusters undergo continual reorganization and, thus, the ability to create heterogeneous libraries of gene clusters from, for example, bacterial or other prokaryote sources is valuable in determining sources of novel proteins, particularly including enzymes such as, for example, the polyketide synthases that are responsible for the synthesis of polyketides having a vast array of useful activities. Other types of proteins that are the product(s) of gene clusters are also contemplated, including, for example, antibiotics, antivirals, antitumor agents and regulatory proteins, such as insulin.

Polyketides are molecules which are an extremely rich source of bioactivities, including antibiotics (such as tetracyclines and erythromycin), anti-cancer agents (daunomycin), immunosuppressants (FK506 and rapamycin), and veterinary products (monensin). Many polyketides (produced by polyketide synthases) are valuable as therapeutic agents. Polyketide synthases are multifunctional enzymes that catalyze the biosynthesis of a huge variety of carbon chains differing in length and patterns of functionality and cyclization. Polyketide synthase genes fall into gene clusters and at least one type (designated type I) of polyketide synthases have large size genes and enzymes, complicating genetic manipulation and *in vitro* studies of these genes/proteins.

The ability to select and combine desired components from a library of polyketides and postpolyketide biosynthesis genes for generation of novel polyketides for study is appealing. The method(s) of the present invention make it possible to and facilitate the cloning of novel polyketide synthases, since one can generate gene banks with clones containing large inserts (especially when using the f-factor based vectors), which facilitates cloning of gene clusters.

Preferably, the gene cluster DNA is ligated into a vector, particularly wherein a vector further comprises expression regulatory sequences which can control and regulate the production of a detectable protein or protein-related array activity from the ligated gene clusters. Use of vectors which have an exceptionally large capacity for exogenous DNA introduction are particularly appropriate for use with such gene clusters and are described by way of example herein to include the f-factor (or fertility factor) of *E. coli*. This f-factor of *E. coli* is a plasmid which affects high-frequency transfer of itself during conjugation and is ideal to

achieve and stably propagate large DNA fragments, such as gene clusters from mixed microbial samples.

The DNA can then be isolated by available techniques that are described in the literature. The IsoQuick[®] nucleic acid extraction kit (MicroProbe Corporation) is suitable for this purpose.

The DNA isolated or derived from these microorganisms can preferably be inserted into a vector or a plasmid prior to probing for selected DNA. Such vectors or plasmids are preferably those containing expression regulatory sequences, including promoters, enhancers and the like. Such polynucleotides can be part of a vector and/or a composition and still be isolated, in that such vector or composition is not part of its natural environment. Particularly preferred phage or plasmid and methods for introduction and packaging into them are described in detail in the protocol set forth herein.

The following outlines a general procedure for producing libraries from both culturable and non-culturable organisms, which libraries can be probed to select therefrom DNA sequences which hybridize to specified probe DNA:

ENVIRONMENTAL SAMPLE

Obtain Biomass

DNA Isolation (various methods)

Shear DNA (25 gauge needle)

Blunt DNA (Mung Bean Nuclease)

Methylate DNA (EcoR I Methylase)

Ligate to EcoR I linkers (GGAATTCC)

Cut back linkers (EcoR I Restriction Endonuclease)

Size Fractionate (Sucrose Gradient)

Ligate to lambda vector (lambda Zap II and gt11)

Package (in vitro lambda packaging extract)

Plate on *E. coli* host and amplify

Clones having an enzyme activity of interest are identified by screening. This screening can be done either by hybridization, to identify the presence of DNA coding for the enzyme of interest or by detection of the enzymatic activity of interest.

The probe DNA used for selectively isolating the target DNA of interest from the DNA derived from at least one microorganism can be a full-length coding region sequence or a partial coding region sequence of DNA for an enzyme of known activity. The original DNA library can be preferably probed using mixtures of probes comprising at least a portion of DNA sequences encoding enzymes having the specified enzyme activity. These probes or probe libraries are preferably single-stranded and the microbial DNA which is probed has preferably been converted into single-stranded form. The probes that are particularly suitable are those derived from DNA encoding enzymes having an activity similar or identical to the specified enzyme activity which is to be screened.

The probe DNA should be at least about 10 bases and preferably at least 15 bases. In one embodiment, the entire coding region may be employed as a probe. Conditions for the hybridization in which target DNA is selectively isolated by the use of at least one DNA probe will be designed to provide a hybridization stringency of at least about 50% sequence identity, more particularly a stringency providing for a sequence identity of at least about 70%, preferably 75%.

Hybridization techniques for probing a microbial DNA library to isolate target DNA of potential interest are well known in the art and any of those which are described in the literature are suitable for use herein, particularly those which use a solid phase-bound,

directly or indirectly bound, to probe DNA for separation from the remainder of the DNA derived from the microorganisms. Solution phase hybridizations followed by binding of the probe to a solid phase is preferable.

Preferably the probe DNA is "labeled" with one partner of a specific binding pair (i.e. a ligand) and the other partner of the pair is bound to a solid matrix to provide ease of separation of target from its source. The ligand and specific binding partner can be selected from, in either orientation, the following: (1) an antigen or hapten and an antibody or specific binding fragment thereof; (2) biotin or iminobiotin and avidin or streptavidin; (3) a sugar and a lectin specific therefor; (4) an enzyme and an inhibitor therefor; (5) an apoenzyme and cofactor; (6) complementary homopolymeric oligonucleotides; and (7) a hormone and a receptor therefor. The solid phase is preferably selected from: (1) a glass or polymeric surface; (2) a packed column of polymeric beads; and (3) magnetic or paramagnetic particles.

The library of clones prepared as described above can be screened directly for enzymatic activity without the need for culture expansion, amplification or other supplementary procedures. However, in one preferred embodiment, it is considered desirable to amplify the DNA recovered from the individual clones such as by PCR.

Further, it is optional but desirable to perform an amplification of the target DNA that has been isolated. In this embodiment the target DNA is separated from the probe DNA after isolation. It is then amplified before being used to transform hosts. The double stranded DNA selected to include as at least a portion thereof a predetermined DNA sequence can be rendered single stranded, subjected to amplification and reannealed to provide amplified numbers of selected double stranded

DNA. Numerous amplification methodologies are now well known in the art.

The selected DNA is then used for preparing a library for screening by transforming a suitable organism. Hosts, particularly those specifically identified herein as preferred, are transformed by artificial introduction of the vectors containing the target DNA by inoculation under conditions conducive for such transformation. One could transform with double stranded circular or linear DNA or there may also be instances where one would transform with single stranded circular or linear DNA.

The resultant libraries of transformed clones are then screened for clones which display activity for the enzyme of interest in a phenotypic assay for enzyme activity.

Having prepared a multiplicity of clones from DNA selectively isolated from an organism, such clones are screened for a specific enzyme activity and to identify the clones having the specified enzyme characteristics.

The screening for enzyme activity may be effected on individual expression clones or may be initially effected on a mixture of expression clones to ascertain whether or not the mixture has one or more specified enzyme activities. If the mixture has a specified enzyme activity, then the individual clones may be rescreened for such enzyme activity or for a more specific activity. Thus, for example, if a clone mixture has hydrolase activity, then the individual clones may be recovered and screened to determine which of such clones has hydrolase activity.

As representative examples of expression vectors which may be used there may be mentioned viral particles,

baculovirus, phage, plasmids, phagemids, cosmids, phosmids, bacterial artificial chromosomes, viral DNA (e.g. vaccinia, adenovirus, fowl pox virus, pseudorabies and derivatives of SV40), P1-based artificial chromosomes, yeast plasmids, yeast artificial chromosomes, and any other vectors specific for specific hosts of interest (such as bacillus, aspergillus, yeast, etc.) Thus, for example, the DNA may be included in any one of a variety of expression vectors for expressing a polypeptide. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences. Large numbers of suitable vectors are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example; Bacterial: pQE70, pQE60, pQE-9 (Qiagen), psiX174, pBluescript SK, pBluescript KS (Stratagene); pTRC99a, pKK223-3, pKK233-3, pDR540, pRIT2T (Pharmacia); Eukaryotic: pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene), pSVK3, pBPV, pMSG, pSVLSV40 (Pharmacia). However, any other plasmid or vector may be used as long as they are replicable and viable in the host.

A particularly preferred type of vector for use in the present invention contains an f-factor origin replication. The f-factor (or fertility factor) in *E. coli* is a plasmid which effects high frequency transfer of itself during conjugation and less frequent transfer of the bacterial chromosome itself. A particularly preferred embodiment is to use cloning vectors, referred to as "fosmids" or bacterial artificial chromosome (BAC) vectors. These are derived from *E. coli* f-factor which is able to stably integrate large segments of DNA. When integrated with DNA from a mixed uncultured environmental sample, this makes it possible to achieve large genomic fragments in the form of a stable "environmental DNA library."

The DNA derived from a microorganism(s) may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.

The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. Particular named bacterial promoters include *lacI*, *lacZ*, T3, T7, *gpt*, *lambda P_R*, *P_L* and *trp*. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression. Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers.

In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in *E. coli*.

Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of *E. coli* and *S. cerevisiae* TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons

encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), α -factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium.

The DNA selected and isolated as hereinabove described is introduced into a suitable host to prepare a library which is screened for the desired enzyme activity. The selected DNA is preferably already in a vector which includes appropriate control sequences whereby selected DNA which encodes for an enzyme may be expressed, for detection of the desired activity. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).

As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such as *E. coli*, *Streptomyces*, *Salmonella typhimurium*; fungal cells, such as yeast; insect cells such as *Drosophila* S2 and *Spodoptera Sf9*; animal cells such as CHO, COS or Bowes melanoma; adenoviruses; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.

With particular references to various mammalian cell culture systems that can be employed to express recombinant protein, examples of mammalian expression systems include the COS-7 lines of monkey kidney

fibroblasts, described by Gluzman, Cell, 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

Host cells are genetically engineered (transduced or transformed or transfected) with the vectors. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying genes. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

The library may be screened for a specified enzyme activity by procedures known in the art. For example, the enzyme activity may be screened for one or more of the six IUB classes; oxidoreductases, transferases, hydrolases, lyases, isomerases and ligases. The recombinant enzymes which are determined to be positive for one or more of the IUB classes may then be rescreened for a more specific enzyme activity.

Alternatively, the library may be screened for a more specialized enzyme activity. For example, instead of generically screening for hydrolase activity, the library may be screened for a more specialized activity, i.e. the type of bond on which the hydrolase acts. Thus, for example, the library may be screened to ascertain those hydrolases which act on one or more specified

chemical functionalities, such as: (a) amide (peptide bonds), i.e. proteases; (b) ester bonds, i.e. esterases and lipases; (c) acetals, i.e., glycosidases etc.

The clones which are identified as having the specified enzyme activity may then be sequenced to identify the DNA sequence encoding an enzyme having the specified activity. Thus, in accordance with the present invention it is possible to isolate and identify: (i) DNA encoding an enzyme having a specified enzyme activity, (ii) enzymes having such activity (including the amino acid sequence thereof) and (iii) produce recombinant enzymes having such activity.

Alternatively, clones found to have the enzymatic activity for which the screen was performed are sequenced and then subjected to directed mutagenesis to develop new enzymes with desired activities or to develop modified enzymes with particularly desired properties that are absent or less pronounced in the wild-type enzyme, such as stability to heat or organic solvents. Any of the known techniques for directed mutagenesis are applicable to the invention. For example, particularly preferred mutagenesis techniques for use in accordance with the invention include those discussed below.

The present invention may be employed for example, to identify or produce new enzymes having, for example, the following activities which may be employed for the following uses:

1 **Lipase/Esterase**

- a. Enantioselective hydrolysis of esters (lipids)/thioesters
 - 1) Resolution of racemic mixtures
 - 2) Synthesis of optically active acids or alcohols from meso-diesters

- b. Selective syntheses
 - 1) Regiospecific hydrolysis of carbohydrate esters
 - 2) Selective hydrolysis of cyclic secondary alcohols
 - c. Synthesis of optically active esters, lactones, acids, alcohols
 - 1) Transesterification of activated/nonactivated esters
 - 2) Interesterification
 - 3) Optically active lactones from hydroxyesters
 - 4) Regio- and enantioselective ring opening of anhydrides
 - d. Detergents
 - e. Fat/Oil conversion
 - f. Cheese ripening
- 2 **Protease**
- a. Ester/amide synthesis
 - b. Peptide synthesis
 - c. Resolution of racemic mixtures of amino acid esters
 - d. Synthesis of non-natural amino acids
 - e. Detergents/protein hydrolysis
- 3 **Glycosidase/Glycosyl transferase**
- a. Sugar/polymer synthesis
 - b. Cleavage of glycosidic linkages to form mono, di-and oligosaccharides
 - c. Synthesis of complex oligosaccharides
 - d. Glycoside synthesis using UDP-galactosyl transferase
 - e. Transglycosylation of disaccharides, glycosyl fluorides, aryl galactosides
 - f. Glycosyl transfer in oligosaccharide synthesis
 - g. Diastereoselective cleavage of β -glucosylsulfoxides
 - h. Asymmetric glycosylations

- i. Food processing
- j. Paper processing

4 Phosphatase/Kinase

- a. Synthesis/hydrolysis of phosphate esters
 - 1) Regio-, enantioselective phosphorylation
 - 2) Introduction of phosphate esters
 - 3) Synthesize phospholipid precursors
 - 4) Controlled polynucleotide synthesis
- b. Activate biological molecule
- c. Selective phosphate bond formation without protecting groups

5 Mono/Dioxygenase

- a. Direct oxyfunctionalization of unactivated organic substrates
- b. Hydroxylation of alkane, aromatics, steroids
- c. Epoxidation of alkenes
- d. Enantioselective sulphoxidation
- e. Regio- and stereoselective Bayer-Villiger oxidations

6 Haloperoxidase

- a. Oxidative addition of halide ion to nucleophilic sites
- b. Addition of hypohalous acids to olefinic bonds
- c. Ring cleavage of cyclopropanes
- d. Activated aromatic substrates converted to ortho and para derivatives
- e. 1,3 diketones converted to 2-halo-derivatives
- f. Heteroatom oxidation of sulfur and nitrogen containing substrates
- g. Oxidation of enol acetates, alkynes and activated aromatic rings

7 Lignin peroxidase/Diarylpropane peroxidase

- a. Oxidative cleavage of C-C bonds
- b. Oxidation of benzylic alcohols to aldehydes

- c. Hydroxylation of benzylic carbons
 - d. Phenol dimerization
 - e. Hydroxylation of double bonds to form diols
 - f. Cleavage of lignin aldehydes
- 8 Epoxide hydrolase
- a. Synthesis of enantiomerically pure bioactive compounds
 - b. Regio- and enantioselective hydrolysis of epoxide
 - c. Aromatic and olefinic epoxidation by monooxygenases to form epoxides
 - d. Resolution of racemic epoxides
 - e. Hydrolysis of steroid epoxides
- 9 Nitrile hydratase/nitrilase
- a. Hydrolysis of aliphatic nitriles to carboxamides
 - b. Hydrolysis of aromatic, heterocyclic, unsaturated aliphatic nitriles to corresponding acids
 - c. Hydrolysis of acrylonitrile
 - d. Production of aromatic and carboxamides, carboxylic acids (nicotinamide, picolinamide, isonicotinamide)
 - e. Regioselective hydrolysis of acrylic dinitrile
 - f. α -amino acids from α -hydroxynitriles
- 10 Transaminase
- a. Transfer of amino groups into oxo-acids
- 11 Amidase/Acylase
- a. Hydrolysis of amides, amidines, and other C-N bonds
 - b. Non-natural amino acid resolution and synthesis

The following examples illustrate the invention but are not a limitation of its scope.

Example 1Preparation of a Mammalian DNA Library

The following outlines the procedures used to generate a gene library from a sample of the exterior surface of a whale bone found at 1240 meters depth in the Santa Catalina Basin during a dive expedition.

Isolate DNA.

IsoQuick Procedure as per manufacturer's instructions.

Shear DNA

1. Vigorously push and pull DNA through a 25G double-hub needle and 1-cc syringes about 500 times.
2. Check a small amount (0.5 μ g) on a 0.8% agarose gel to make sure the majority of the DNA is in the desired size range (about 3-6 kb).

Blunt DNA

1. Add:

H ₂ O	to a final volume of 405 μ l
45 μ l	10X Mung Bean Buffer
2.0 μ l	Mung Bean Nuclease

(150 u/ μ l)

2. Incubate 37°C, 15 minutes.
3. Phenol/chloroform extract once.
4. Chloroform extract once.
5. Add 1 ml ice cold ethanol to precipitate.
6. Place on ice for 10 minutes.
7. Spin in microfuge, high speed, 30 minutes.
8. Wash with 1 ml 70% ethanol.
9. Spin in microfuge, high speed, 10 minutes

and dry.

Methylate DNA

1. Gently resuspend DNA in 26 μ l TE.
2. Add:

	4.0 μ l	10X EcoR I Methylase
Buffer	0.5 μ l	SAM (32 mM)
	5.0 μ l	EcoR I Methylase (40 u/ μ l)
3. Incubate 37°, 1 hour.

Insure Blunt Ends

1. Add to the methylation reaction:

5.0 μ l	100 mM MgCl ₂
8.0 μ l	dNTP mix (2.5 mM of each dGTP, dATP, dTTP, dCTP)
4.0 μ l	Klenow (5 u/ μ l)
2. Incubate 12°C, 30 minutes.
3. Add 450 μ l 1X STE.
4. Phenol/chloroform extract once.
5. Chloroform extract once.
6. Add 1 ml ice cold ethanol to precipitate and place on ice for 10 minutes.
7. Spin in microfuge, high speed, 30 minutes.
8. Wash with 1 ml 70% ethanol.
9. Spin in microfuge, high speed, 10 minutes and dry.

Linker Ligation

1. Gently resuspend DNA in 7 μ l Tris-EDTA (TE).
2. Add:

14 μ l	Phosphorylated EcoR I linkers (200 ng/ μ l)
3.0 μ l	10X Ligation Buffer
3.0 μ l	10 mM rATP
3.0 μ l	T4 DNA Ligase (4Wu/ μ l)
3. Incubate 4°C, overnight.

EcoRI Cutback

1. Heat kill ligation reaction 68°C, 10 minutes.
2. Add:
237.9 μ l H₂O
30 μ l 10X EcoR I Buffer
2.1 μ l EcoR I Restriction Enzyme (100 u/ μ l)
3. Incubate 37°C, 1.5 hours.
4. Add 1.5 μ l 0.5 M EDTA.
5. Place on ice.

Sucrose Gradient (2.2 ml) Size Fractionation

1. Heat sample to 65°C, 10 minutes.
2. Gently load on 2.2 ml sucrose gradient.
3. Spin in mini-ultracentrifuge, 45K, 20°C, 4 hours (no brake).
4. Collect fractions by puncturing the bottom of the gradient tube with a 20G needle and allowing the sucrose to flow through the needle. Collect the first 20 drops in a Falcon 2059 tube then collect 10 1-drop fractions (labelled 1-10). Each drop is about 60 μ l in volume.
5. Run 5 μ l of each fraction on a 0.8% agarose gel to check the size.
6. Pool fractions 1-4 (about 10-1.5 kb) and, in a separate tube, pool fractions 5-7 (about 5-0.5 kb).
7. Add 1 ml ice cold ethanol to precipitate and place on ice for 10 minutes.
8. Spin in microfuge, high speed, 30 minutes.
9. Wash with 1 ml 70% ethanol.
10. Spin in microfuge, high speed, 10 minutes and dry.
11. Resuspend each in 10 μ l TE buffer.

Test Ligation to Lambda Arms

1. Plate assay to get an approximate concentration. Spot 0.5 μ l of the sample on agarose containing ethidium bromide along with standards (DNA samples of known concentration). View in UV light and estimate concentration compared to the standards. Fraction 1-4 = >1.0 μ g/ μ l. Fraction 5-7 = 500 ng/ μ l.
2. Prepare the following ligation reactions (5 μ l reactions) and incubate 4°C, overnight:

Sample	H ₂ O	10X Ligase Buffer	10mM rATP	Lambda arms (gt11 and ZAP)	Insert DNA	T4 DNA Ligase (4 Wu/ μ)
Fraction 1-4	0.5 μ l	0.5 μ l	0.5 μ l	1.0 μ l	2.0 μ l	0.5 μ l
Fraction 5-7	0.5 μ l	0.5 μ l	0.5 μ l	1.0 μ l	2.0 μ l	0.5 μ l

Test Package and Plate

1. Package the ligation reactions following manufacturer's protocol. Package 2.5 μ l per packaging extract (2 extracts per ligation).
2. Stop packaging reactions with 500 μ l SM buffer and pool packaging that came from the same ligation.
3. Titer 1.0 μ l of each on appropriate host (OD₆₀₀ = 1.0) [XLI-Blue MRF for ZAP and Y1088 for gt11]

Add 200 μ l host (in mM MgSO₄) to

Falcon 2059 tubes

Inoculate with 1 μ l packaged phage

Incubate 37°C, 15 minutes

Add about 3 ml 48°C top agar
[50 ml stock containing 150 μ l
IPTG (0.5M) and 300 μ l X-GAL
(350 mg/ml)]

Plate on 100mm plates and incubate
37°C, overnight.

4. Efficiency results:

gt11: 1.7 x 10⁴ recombinants
with 95% background

ZAP II: 4.2 x 10⁴ recombinants with
66% background

Contaminants in the DNA sample may have inhibited
the enzymatic reactions, though the sucrose gradient
and organic extractions may have removed them.
Since the DNA sample was precious, an effort was
made to "fix" the ends for cloning:

Re-Blunt DNA

1. Pool all left over DNA that was not
ligated to the lambda arms (Fractions 1-7)
and add H₂O to a final volume of 12 μ l.

Then add:

143 μ l	H ₂ O
20 μ l	10X Buffer 2 (from Stratagene's cDNA Synthesis Kit)
23 μ l	Blunting dNTP (from Stratagene's cDNA Synthesis Kit)
2.0 μ l	Pfu (from Stratagene's

cDNA Synthesis Kit)

2. Incubate 72°C, 30 minutes.
3. Phenol/chloroform extract once.
4. Chloroform extract once.
5. Add 20 μ L 3M NaOAc and 400 μ l ice cold
ethanol to precipitate.
6. Place at -20°C, overnight.
7. Spin in microfuge, high speed, 30 minutes.

8. Wash with 1 ml 70% ethanol.
 9. Spin in microfuge, high speed, 10 minutes and dry.
- (Do NOT Methylate DNA since it was already methylated in the first round of processing)

Adaptor Ligation

1. Gently resuspend DNA in 8 μ l EcoR I adaptors (from Stratagene's cDNA Synthesis Kit).
 2. Add:

1.0 μ l	10X Ligation Buffer
1.0 μ l	10 mM rATP
1.0 μ l	T4 DNA Ligase (4Wu/ μ l)
 3. Incubate 4°C, 2 days.
- (Do NOT cutback since using ADAPTORS this time. Instead, need to phosphorylate)

Phosphorylate Adaptors

1. Heat kill ligation reaction 70°C, 30 minutes.
- Add:
- | | |
|-------------|------------------------|
| 1.0 μ l | 10X Ligation Buffer |
| 2.0 μ l | 10mM rATP |
| 6.0 μ l | H ₂ O |
| 1.0 μ l | PNK (from Stratagene's |
- cDNA Synthesis Kit).
3. Incubate 37°C, 30 minutes.
 4. Add 31 μ l H₂O and 5 μ l 10X STE.
 5. Size fractionate on a Sephacryl S-500 spin column (pool fractions 1-3).
 6. Phenol/chloroform extract once.
 7. Chloroform extract once.
 8. Add ice cold ethanol to precipitate.
 9. Place on ice, 10 minutes.
 10. Spin in microfuge, high speed, 30 minutes.
 11. Wash with 1 ml 70% ethanol.

12. Spin in microfuge, high speed, 10 minutes and dry.

13. Resuspend in 10.5 μ l TE buffer.

Do not plate assay. Instead, ligate directly to arms as above except use 2.5 μ l of DNA and no water.

Package and titer as above.

Efficiency results:

gt11: 2.5 x 10⁶ recombinants with
2.5% background

ZAP II: 9.6 x 10⁵ recombinants with 0%
background

Amplification of Libraries (5.0 x 10⁵ recombinants
from each library)

1. Add 3.0 ml host cells (OD₆₀₀=1.0) to two 50 ml conical tube.
2. Inoculate with 2.5 X 10⁵ pfu per conical tube.
3. Incubate 37°C, 20 minutes.
4. Add top agar to each tube to a final volume of 45 ml.
5. Plate the tube across five 150 mm plates.
6. Incubate 37°C, 6-8 hours or until plaques are about pin-head in size.
7. Overlay with 8-10 ml SM Buffer and place at 4°C overnight (with gentle rocking if possible).

Harvest Phage

1. Recover phage suspension by pouring the SM buffer off each plate into a 50-ml conical tube.
2. Add 3 ml chloroform, shake vigorously and incubate at room temperature, 15 minutes.
3. Centrifuge at 2K rpm, 10 minutes to remove cell debris.

4. Pour supernatant into a sterile flask, add 500 μ l chloroform.
5. Store at 4°C.

Titer Amplified Library

1. Make serial dilutions:
10⁻⁵ = 1 μ l amplified phage in 1 ml SM Buffer
10⁻⁶ = 1 μ l of the 10⁻⁵ dilution in 1 ml SM Buffer
2. Add 200 μ l host (in 10 mM MgSO₄) to two tubes.
3. Inoculate one with 10 μ l 10⁻⁵ dilution (10⁻⁵).
4. Inoculate the other with 1 μ l 10⁻⁶ dilution (10⁻⁶).
5. Incubate 37°C, 15 minutes.
6. Add about 3 ml 48°C top agar.
[50 ml stock containing 150 μ l IPTG (0.5M) and 375 μ l X-GAL (350 mg/ml)]
7. Plate on 100 mm plates and incubate 37°C, overnight.
8. Results:
gt11: 1.7 x 10¹¹/ml
ZAP II: 2.0 x 10¹⁰/ml

Example 2Construction of a Stable, Large Insert DNA Library of
Picoplankton Genomic DNA

Cell collection and preparation of DNA. Agarose plugs containing concentrated picoplankton cells were prepared from samples collected on an oceanographic cruise from Newport, Oregon to Honolulu, Hawaii. Seawater (30 liters) was collected in Niskin bottles, screened through 10 μm Nitex, and concentrated by hollow fiber filtration (Amicon DC10) through 30,000 MW cutoff polyulfone filters. The concentrated bacterioplankton cells were collected on a 0.22 μm , 47 mm Durapore filter, and resuspended in 1 ml of 2X STE buffer (1M NaCl, 0.1M EDTA, 10 mM Tris, pH 8.0) to a final density of approximately 1×10^{10} cells per ml. The cell suspension was mixed with one volume of 1% molten Seaplaque LMP agarose (FMC) cooled to 40°C, and then immediately drawn into a 1 ml syringe. The syringe was sealed with parafilm and placed on ice for 10 min. The cell-containing agarose plug was extruded into 10 ml of Lysis Buffer (10mM Tris pH 8.0, 50 mM NaCl, 0.1M EDTA, 1% Sarkosyl, 0.2% sodium deoxycholate, 1 mg/ml lysozyme) and incubated at 37°C for one hour. The agarose plug was then transferred to 40 mls of ESP Buffer (1% Sarkosyl, 1 mg/ml proteinase K, in 0.5M EDTA), and incubated at 55°C for 16 hours. The solution was decanted and replaced with fresh ESP Buffer, and incubated at 55°C for an additional hour. The agarose plugs were then placed in 50 mM EDTA and stored at 4°C shipboard for the duration of the oceanographic cruise.

One slice of an agarose plug (72 μl) prepared from a sample collected off the Oregon coast was dialyzed overnight at 4°C against 1 mL of buffer A (100mM NaCl, 10mM Bis Tris Propane-HCl, 100 $\mu\text{g/ml}$ acetylated BSA: pH 7.0 @ 25°C) in a 2 mL microcentrifuge tube. The solution was replaced with 250 μl of fresh buffer A containing 10

mM MgCl₂ and 1 mM DTT and incubated on a rocking platform for 1 hr at room temperature. The solution was then changed to 250 μ l of the same buffer containing 4U of Sau3A1 (NEB), equilibrated to 37°C in a water bath, and then incubated on a rocking platform in a 37°C incubator for 45 min. The plug was transferred to a 1.5 ml microcentrifuge tube and incubated at 68°C for 30 min to inactivate the enzyme and to melt the agarose. The agarose was digested and the DNA dephosphorylated using Gelase and HK-phosphatase (Epicentre), respectively, according to the manufacturer's recommendations. Protein was removed by gentle phenol/chloroform extraction and the DNA was ethanol precipitated, pelleted, and then washed with 70% ethanol. This partially digested DNA was resuspended in sterile H₂O to a concentration of 2.5 ng/ μ l for ligation to the pFOS1 vector.

PCR amplification results from several of the agarose plugs (data not shown) indicated the presence of significant amounts of archaeal DNA. Quantitative hybridization experiments using rRNA extracted from one sample, collected at 200 m of depth off the Oregon Coast, indicated that planktonic archaea in (this assemblage comprised approximately 4.7% of the total picoplankton biomass (this sample corresponds to "PACI"-200 m in Table 1 of DeLong et al., high abundance of Archaea in Antarctic marine picoplankton, *Nature*, 371:695-698, 1994). Results from archaeal-biased rDNA PCR amplification performed on agarose plug lysates confirmed the presence of relatively large amounts of archaeal DNA in this sample. Agarose plugs prepared from this picoplankton sample were chosen for subsequent fosmid library preparation. Each 1 ml agarose plug from this site contained approximately 7.5×10^5 cells, therefore approximately 5.4×10^5 cells were present in the 72 μ l slice used in the preparation of the partially digested DNA.

Vector arms were prepared from pFOS1 as described (Kim et al., Stable propagation of casmid sized human DNA inserts in an F factor based vector, Nucl. Acids Res., 20:10832-10835, 1992). Briefly, the plasmid was completely digested with AatII, dephosphorylated with HK phosphatase, and then digested with BamHI to generate two arms, each of which contained a cos site in the proper orientation for cloning and packaging ligated DNA between 35-45 kbp. The partially digested picoplankton DNA was ligated overnight to the pFOS1 arms in a 15 μ l ligation reaction containing 25 ng each of vector and insert and 1U of T4 DNA ligase (Boehringer-Mannheim). The ligated DNA in four microliters of this reaction was in vitro packaged using the Gigapack XL packaging system (Stratagene), the fosmid particles transfected to *E. coli* strain DH10B (BRL), and the cells spread onto LB_{cm15} plates. The resultant fosmid clones were picked into 96-well microliter dishes containing LB_{cm15} supplemented with 7% glycerol. Recombinant fosmids, each containing ca. 40 kb of picoplankton DNA insert, yielded a library of 3.552 fosmid clones, containing approximately 1.4×10^8 base pairs of cloned DNA. All of the clones examined contained inserts ranging from 38 to 42 kbp. This library was stored frozen at -80°C for later analysis.

Example 3

Hybridization Selection and Production of Expression Library

Starting with a plasmid library prepared as described in Example 1, hybridization selection and preparation of the expression library were performed according to the protocol described in this example. The library can contain DNA from isolated microorganisms, enriched cultures or environmental samples.

Single-stranded DNA is made in one of two ways: 1)
The plasmid library can be grown and the double-stranded

plasmid DNA isolated. The double-stranded DNA is made single-stranded using F1 gene II protein and Exonuclease III. The gene II protein nicks the double-stranded plasmids at the F1 origin and the Exo III digests away the nicked strand leaving a single-stranded circle. This method is used by Life Technologies in their GeneTrapper™ kit; 2) the second method involves the use of a helper phage to "rescue" one of the strands of the double-stranded plasmids. The plasmid library is grown in a small overnight culture. A small aliquot of this is mixed with VCS-M13 helper phage and again grown overnight. The next morning the phagemids (virus particles containing single-stranded DNA) are recovered from the media and used in the following protocol.

PROTOCOL

1. Six samples of 4 μ g of rescued, single-stranded DNA from library #17 were prepared in 3X SSC buffer. Final reaction volumes were 30 μ l.
2. To these solutions was added one of the following:
 - a) nothing
 - b) 100 ng of biotinylated probe from an unrelated sequence
 - c,d) 100 ng of biotinylated probe from organism #13 DNA polymerase gene
 - e,f) 100 ng of biotinylated probe from organism #17 DNA polymerase gene

Biotinylated probes were prepared by PCR amplification of fragments of ~1300 bp in length coding for a portion of the DNA polymerase gene of these organisms. The amplification products were made using biotinylated dUTP in the amplification mix. This modified nucleotide is incorporated throughout the DNA during synthesis. Unincorporated nucleotides were removed using the QIAGEN PCR Clean-up kit.

3. These mixtures were denatured by heating to 95°C for 2 minutes.
4. Hybridization was performed for 90 minutes at 70°C for samples a, b, d and f. Samples c and e were hybridized at 60°C.
5. 50 µl of washed and blocked MPG beads were added and mixed to each sample. These mixtures were agitated every 5 minutes for a total of 30 minutes. MPG beads are sent at 1 mg/ml in buffer containing preservative so 6 sets of 100 µl were washed 2 times in 3X SSC and resuspended in 60 µl of 3X SSC containing 100 µg of sonicated salmon sperm DNA.
6. The DNA/bead mixtures were washed 2 times at room temperature in 0.1X SSC/0.1% SDS, 2 times at 42°C in 0.1X SSC/0.1% SDS for 10 minutes each and 1 additional wash at room temperature with 3X SSC.
7. The bound DNA was eluted by heating the beads to 70°C for 15 minutes in 50 µl TE.
8. Dilutions of the eluted DNAs were made and PCR amplification was performed with either gene specific primers or vectors specific primers. Dilutions of the library DNA were used as standards.
9. The DNA inserts contained within the DNA were amplified by PCR using vector specific primers. These inserts were cloned using the TA Cloning system (Invitrogen).
10. Duplicates of 92 white colonies and 4 blue colonies from samples d and f were grown overnight and colony lifts were prepared for Southern blotting.

11. The digoxigenin system from Boehringer Mannheim was used to probe the colonies using the organism #17 probe.

RESULTS

PCR Quantitation

Figures 1A and 1B. Figure 1A is a photograph of the autoradiogram resulting from the Southern hybridization agarose gel electrophoresis columns of DNA from sample solutions a-f in Example 2, when hybridized with gene specific primers. Figure 1B is a photograph of the autoradiogram resulting from the Southern hybridization agarose gel electrophoresis columns of DNA from sample solutions a-f in Example 2, when hybridized with vector specific primers.

The gene specific DNA amplifications of samples a and b demonstrate that non-specific binding to the beads is minimal. The amount of DNA bound under the other conditions results in the following estimates of enrichment.

	<u>gene specific equivalent</u>	<u>total</u>	<u>enrichment</u>
c	50 ng	100 pg	500X
d	50 ng	30 pg	1667X
e	20 ng	50 pg	400X
f	20 ng	20 pg	1000X

Colony Hybridization

Figure 2 is a photograph of four colony hybridization plates resulting from Plates A and B show positive clones i.e., colonies containing sequences contained in the probe and which contain DNA from a library prepared in accordance with the invention.

Plates C and D were controls and showed no positive clones.

Seven of 92 colonies from the panned sample were positive for sequences contained in the probe. No positive clones were found in the unpanned sample.

Example 4

Enzymatic Activity Assay

The following is a representative example of a procedure for screening an expression library, prepared in accordance with Example 1, for hydrolase activity.

Plates of the library prepared as described in Example 1 are used to multiply inoculate a single plate containing 200 μ L of LB Amp/Meth, glycerol in each well. This step is performed using the High Density Replicating Tool (HDRT) of the Beckman Biomek with a 1% bleach, water, isopropanol, air-dry sterilization cycle between each inoculation. The single plate is grown for 2h at 37°C and is then used to inoculate two white 96-well Dynatech microtiter daughter plates containing 250 μ L of LB Amp/Meth, glycerol in each well. The original single plate is incubated at 37°C for 18h, then stored at -80°C. The two condensed daughter plates are incubated at 37°C also for 18 h. The condensed daughter plates are then heated at 70°C for 45 min. to kill the cells and inactivate the host *E. coli* enzymes. A stock solution of 5mg/mL morphourea phenylalanyl-7-amino-4-trifluoromethyl coumarin (MuPheAFC, the 'substrate') in DMSO is diluted to 600 μ M with 50 mM pH 7.5 Hepes buffer containing 0.6 mg/mL of the detergent dodecyl maltoside.

MuPheAFC

Fifty μL of the 600 μM MuPheAFC solution is added to each of the wells of the white condensed plates with one 100 μL mix cycle using the Biomek to yield a final concentration of substrate of $\sim 100 \mu\text{M}$. The fluorescence values are recorded (excitation = 400 nm, emission = 505 nm) on a plate reading fluorometer immediately after addition of the substrate ($t=0$). The plate is incubated at 70°C for 100 min, then allowed to cool to ambient temperature for 15 additional minutes. The fluorescence values are recorded again ($t=100$). The values at $t=0$ are subtracted from the values at $t=100$ to determine if an active clone is present.

The data will indicate whether one of the clones in a particular well is hydrolyzing the substrate. In order to determine the individual clone which carries the activity, the source library plates are thawed and the individual clones are used to singly inoculate a new plate containing LB Amp/Meth, glycerol. As above, the plate is incubated at 37°C to grow the cells, heated at 70°C to inactivate the host enzymes, and 50 μL of 600 μM MuPheAFC is added using the Biomek.

After addition of the substrate the $t=0$ fluorescence values are recorded, the plate is incubated at 70°C , and the $t=100$ min. values are recorded as above. These data indicate which plate the active clone is in.

The enantioselectivity value, E , for the substrate is determined according to the equation below:

$$\ln[(1-c(1+ee_p))]$$

$$E = \frac{\ln[(1-c(1-ee_p))]}{\ln(1-ee_p)}$$

where ee_p = the enantiomeric excess (ee) of the hydrolyzed product and c = the percent conversion of the reaction. See Wong and Whitesides, *Enzymes in Synthetic Organic Chemistry*, 1994, Elsevier, Tarrytown, New York, pp. 9-12.

The enantiomeric excess is determined by either chiral high performance liquid chromatography (HPLC) or chiral capillary electrophoresis (CE). Assays are performed as follows: two hundred μ L of the appropriate buffer is added to each well of a 96-well white microtiter plate, followed by 50 μ L of partially or completely purified enzyme solution; 50 μ L of substrate is added and the increase in fluorescence monitored versus time until 50% of the substrate is consumed or the reaction stops, whichever comes first.

Example 5

Mutagenesis of Positive Enzyme Activity Clones

Mutagenesis was performed on two different enzymes (alkaline phosphatase and β -glycosidase), using the two different strategies described here, to generate new enzymes which exhibit a higher degree of activity than the wild-type enzymes.

Alkaline Phosphatase

The XL1-Red strain (Stratagene) was transformed with genomic clone 27a3a (in plasmid pBluescript) encoding the alkaline phosphatase gene from the organism OC9a according to the manufacturer's protocol. A 5ml culture of LB + 0.1 mg/ml ampicillin was inoculated with 200 μ l of the transformation. The culture was allowed to grow at 37°C for 30 hours. A miniprep was then performed on the culture, and screening was performed by transforming 2 μ l of the resulting DNA into XL-1 Blue cells (Stratagene) according to the manufacturer's protocol and following

procedure outlined below (after "Transform XL1 Blue cells). The mutated OC9a phosphatase took 10 minutes to develop color and the wild type enzyme took 30 minutes to develop color in the screening assay.

Standard Alkaline Phosphatase Screening Assay

Transform XL1 Red strain → Inoculate 5ml LB/amp culture with 200µl transformation and incubate at 37°C for 30 hours → Miniprep DNA → Transform XL1 Blue cells → Plate on LB/amp plates → Lift colonies with Duralon UV (Stratagene) or HATF (Millipore) membranes → Lyse in chloroform vapors for 30 seconds → Heat kill for 30 minutes at 85°C → Develop filter at room temperature in BCIP buffer → Watch as filter develops and identify and pick fastest developing colonies ("positives") → Restreak "positives" onto a BCIP plate

BCIP Buffer:

20mm CAPS pH 9.0
1mm MgCl₂
0.01 mm ZnCl₂
0.1 mg/ml BCIP

Beta-Glycosidase

This protocol was used to mutagenize Thermococcus 9N2 Beta-Glycosidase.

PCR Reaction

2 microliters dNTP's (10mM Stocks)
10 microliters 10xPCR Buffer
.5 microliters Vector DNA-31G1A-100 nanograms
20 microliters 3' Primer (100 pmol)
20 microliters 5' Primer (100 pmol)
16 microliters MnCl 4H₂O (1.25mM Stock)
24.5 microliters H₂O
1 microliter Taq Polymerase (5.0 Units)
100 microliters total

Reaction Cycle

95°C 15 seconds

58°C 30 seconds

72°C 90 seconds

25 cycles (10 minute extension at 72°C-4°C incubation)

Run 5 microliters on a 1% agarose gel to check the reaction.

Purify on a Qiaquick column (Qiagen).

Resuspend in 50 microliters H₂O.

Restriction Digest

25 microliters purified PCR product

10 microliters NEB Buffer #2

3 microliters Kpn I (10U/microliter)

3 microliters EcoR1 (20U/microliter)

59 microliters H₂O

Cut for 2 hours at 37°C.

Purify on a Qiaquick column (Qiagen).

Elute with 35 microliters H₂O.

Ligation

10 microliters Digested PCR product

5 microliters Vector (cut with EcoRI/KpnI and phosphatased with shrimp alkaline phosphatase

4 microliters 5x Ligation Buffer

1 microliter T4 DNA Ligase (BRL)

Ligate overnight.

Transform into M15pREP4 cells using electroporation.

Plate 100 or 200 microliters onto LB amp meth kan plates, grow overnight at 37 degrees celsius.

Beta-Glycosidase Assay

Perform glycosidase assay to screen for mutants as follows. The filter assay uses buffer Z (see recipe below) containing 1 mg/ml of the substrate 5-bromo-4-chloro-3-indolyl-6-o-glucopyranoside (XGLU) (Diagnostic Chemicals Limited or Sigma).

Z-Buffer: (referenced in Miller, J.H. (1992) A Short Course in Bacterial Genetics, p. 445.)
per liter:

$\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$	16.1 g
$\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$	5.5 g
KCl	0.75 g
$\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$	0.246 g
β -mercaptoethanol	2.7 ml
Adjust pH to 7.0	

(1) Perform colony lifts using Millipore HATF membrane filters.

(2) Lyse colonies with chloroform vapor in 150 mm glass petri dishes.

(3) Transfer filters to 100 mm glass petri dishes containing a piece of Whatman 3MM filter paper saturated with Z buffer containing 1 mg/ml XGLU. After transferring filter bearing lysed colonies to the glass petri dish, maintain dish at room temperature.

(4) "Positives" were observed as blue spots on the filter membranes ("positives" are spots which appear early). Use the following filter rescue technique to retrieve plasmid from lysed positive colony. Use pasteur pipette (or glass capillary tube) to core blue spots on the filter membrane. Place the small filter disk in an Epp tube containing 20 μl water. Incubate the Epp tube at 75°C for 5 minutes followed by vortexing to elute

plasmid DNA off filter. Transform this DNA into electrocompetent *E. coli* cells. Repeat filter-lift assay on transformation plates to identify "positives." Return transformation plates to 37°C incubator after filter lift to regenerate colonies. Inoculate 3 ml LBamp liquid with repurified positives and incubate at 37°C overnight. Isolate plasmid DNA from these cultures and sequence plasmid insert.

Example 7

Directed Mutagenesis of Positive Enzyme Activity Clones

Directed mutagenesis was performed on two different enzymes (alkaline phosphatase and β -glycosidase), using the two different strategies described here, to generate new enzymes which exhibit a higher degree of activity at lower temperatures than the wild-type enzymes.

Alkaline Phosphatase

The XL1-Red strain (Stratagene) was transformed with DNA encoding an alkaline phosphatase (in plasmid pBluescript) from the organism OC9a according to the manufacturer's protocol. A 5ml culture of LB + 0.1 mg/ml ampicillin was inoculated with 200 μ l of the transformation. The culture was allowed to grow at 37°C for 30 hours. A miniprep was then performed on the culture, and screening was performed by transforming 2 μ l of the resulting DNA into XL-1 Blue cells (Stratagene) according to the manufacturer's protocol.

Standard Alkaline Phosphatase Screening Assay

→ Plate on LB/amp plates → Lift colonies with Duralon UV (Stratagene) or HATF (Millipore) membranes → Lyse in chloroform vapors for 30 seconds → Heat kill for 30 minutes at 85°C → Develop filter at room temperature

in BCIP buffer → Watch as filter develops and identify and pick fastest developing colonies ("positives") → Restreak "positives" onto a BCIP plate.

BCIP Buffer:

20mm CAPS pH 9.0
1mm MgCl₂
0.01 mm ZnCl₂
0.1 mg/ml BCIP

The mutated OC9a phosphatase took 10 minutes to develop color and the wild type enzyme took 30 minutes to develop color in the screening assay.

Beta-Glycosidase

This protocol was used to mutagenize DNA encoding Thermococcus 9N2 Beta-Glycosidase. This DNA sequence is set forth in Figure 1.

PCR

2 microliters dNTP's (10mM Stocks)
10 microliters 10xPCR Buffer
.5 microliters pBluescript vector containing Beta-glycosidase DNA (100 nanograms)
20 microliters 3' Primer (100 pmol)
20 microliters 5' Primer (100 pmol)
16 microliters MnCl 4H₂O (1.25mM Stock)
24.5 microliters H₂O
1 microliter Taq Polymerase (5.0 Units)
100 microliters total

Reaction Cycle

95°C 15 seconds
58°C 30 seconds
72°C 90 seconds
25 cycles (10 minute extension at 72°C-4°C incubation)

Run 5 microliters on a 1% agarose gel to check the reaction.

Purify on a Qiaquick column (Qiagen).
Resuspend in 50 microliters H₂O.

Restriction Digest

25 microliters purified PCR product
10 microliters NEB Buffer #2
3 microliters Kpn I (10U/microliter)
3 microliters EcoR1 (20U/microliter)
59 microliters H₂O

Cut for 2 hours at 37°C.
Purify on a Qiaquick column (Qiagen).
Elute with 35 microliters H₂O.

Ligation

10 microliters Digested PCR product
5 microliters pBluescript Vector (cut with
EcoRI/KpnI and phosphatased with shrimp
alkaline phosphatase)
4 microliters 5x Ligation Buffer
1 microliter T4 DNA Ligase (BRL)

Ligate overnight.

Transform into M15pREP4 cells using
electroporation.

Plate 100 or 200 microliters onto LB amp meth
kan plates, grow overnight at 37 degrees
celsius.

Beta-Glycosidase Assay

Perform glycosidase assay to screen for mutants as
follows. The filter assay uses buffer Z (see recipe
below) containing 1 mg/ml of the substrate 5-bromo-4-
chloro-3-indolyl-6-o-glucopyranoside (XGLU) (Diagnostic
Chemicals Limited or Sigma).

Z-Buffer: (referenced in Miller, J.H. (1992) A Short Course in Bacterial Genetics, p. 445.)

per liter:

$\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$	16.1 g
$\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$	5.5 g
KCl	0.75 g
$\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$	0.246 g
6-mercaptoethanol	2.7 ml
Adjust pH to 7.0	

(1) Perform colony lifts using Millipore HATF membrane filters.

(2) Lyse colonies with chloroform vapor in 150 mm glass petri dishes.

(3) Transfer filters to 100 mm glass petri dishes containing a piece of Whatman 3MM filter paper saturated with Z buffer containing 1 mg/ml XGLU. After transferring filter bearing lysed colonies to the glass petri dish, maintain dish at room temperature.

(4) "Positives" were observed as blue spots on the filter membranes ("positives" are spots which appear early). Use the following filter rescue technique to retrieve plasmid from lysed positive colony. Use pasteur pipette (or glass capillary tube) to core blue spots on the filter membrane. Place the small filter disk in an Epp tube containing 20 μl water. Incubate the Epp tube at 75°C for 5 minutes followed by vortexing to elute plasmid DNA off filter. Transform this DNA into electrocompetent *E. coli* cells. Repeat filter-lift assay on transformation plates to identify "positives." Return transformation plates to 37°C incubator after filter lift to regenerate colonies. Inoculate 3 ml LBamp liquid with repurified positives and incubate at 37°C overnight. Isolate plasmid DNA from these cultures and sequence plasmid insert.

The β -glycosidase subjected to mutagenesis acted on XGLU 2.5 times more efficiently than wild-type β -glycosidase.

Numerous modifications and variations of the present invention are possible in light of the above teachings; therefore, within the scope of the claims, the invention may be practiced other than as particularly described.

What Is Claimed Is:

1. A process for identifying clones having a specified enzyme activity, which process comprises:

screening for said specified enzyme activity in a library of clones prepared by

(i) selecting and recovering target nucleic acid from a nucleic acid population derived from at least two microorganisms, by use of at least one nucleic acid or nucleic acid like hybridizing probe comprising at least a portion of a nucleic acid sequence encoding a protein having a specified activity; and

(ii) transforming a host with recovered target nucleic acid to produce a library of clones comprised of a subset of the original nucleic acid population which are screened for a specified activity.

2. The process of claim 1 wherein the nucleic acid obtained from the nucleic acid of the microorganism is selected by:

converting double stranded nucleic acid into single stranded nucleic acid;

recovering from the converted single stranded nucleic acid target single stranded nucleic acid which hybridizes to probe nucleic acid; and

converting recovered single stranded target nucleic acid to double stranded nucleic acid for transforming the host.

3. The process of claim 2 wherein the probe is directly or indirectly bound to a solid phase by which it is separated from single stranded nucleic acid which is not so hybridized.

4. The process of claim 3 which further comprises the steps of:

releasing single stranded nucleic acid from said probe; and

amplifying the single stranded nucleic acid so released prior to converting it to double stranded nucleic acid.

5. The process of Claim 1 wherein said target nucleic acid encodes a gene cluster or portion thereof.

6. A process in which a nucleic acid library derived from at least one microorganism is subjected to a selection procedure to select therefrom double-stranded nucleic acid which hybridizes to one or more probe nucleic acid sequences which is all or a portion of a nucleic acid sequence encoding a protein having the specified protein activity, which process comprises:

(a) contacting the double-stranded nucleic acid population with the nucleic acid probe bound to a ligand under conditions permissive of hybridization so as to produce a complex of probe and members of the nucleic acid population which hybridize thereto;

(b) contacting the complex of (a) with a solid phase specific binding partner for said ligand so as to produce a solid phase complex;

(c) separating the solid phase complex from the unbound nucleic acid population of (b);

(d) releasing from the probe the members of the population which had bound to the solid phase bound probe;

(e) introducing the double-stranded nucleic acid of (d) into a suitable host to form a library containing a plurality of clones containing the selected nucleic acid; and

(f) screening the library for the specified protein activity.

7. The process of Claim 6 wherein said target nucleic acid encodes a gene cluster or portion thereof.

8. The process of Claim 6 which further comprises, before (a) above, the steps of:

(i). contacting the double-stranded nucleic acid population of (a) with a ligand-bound oligonucleotide probe that is complementary to consensus sequences in (i) unique to a given class of proteins under conditions permissive of hybridization to form a double-stranded complex;

(ii). contacting the complex of (i) with a solid phase specific binding partner for said ligand so as to produce a solid phase complex;

(iii) separating the solid phase complex from the unbound nucleic acid population;

(iv) releasing the members of the population which had bound to said solid phase bound probe; and

(v) separating the solid phase bound probe from the members of the population which had bound thereto.

9. A process for obtaining a protein having a specified protein activity derived from a heterogeneous nucleic acid population, which process comprises:

screening, for the specified enzyme activity, a library of clones containing nucleic acid from the heterogeneous nucleic acid population which have been modified or mutagenized towards production of the specified activity.

10. The process of claim 9 which further comprises, prior to said mutagenesis, selectively recovering from the heterogeneous nucleic acid population nucleic acid which comprises nucleic acid sequences coding for a common characteristic, which can be the same or different from the specified activity.

11. The process of claim 10 wherein recovering the nucleic acid preparation comprises contacting the nucleic acid population with a specific binding partner for at least a portion of the sequences.

12. The process of claim 11 wherein the specific binding partner is a solid phase bound hybridization probe.

13. The process of claim 10 wherein the common characteristic is a class of enzyme activity.

14. The process of claim 13 which comprises recovering nucleic acid from clones containing nucleic acid from the heterogeneous nucleic acid population which exhibit the class of enzyme activity.

15. The process of claim 9 wherein the mutagenesis is site-specific or random directed mutagenesis.

16. The process of claim 9 which further comprises prescreening said library of clones for an activity, which can be the same or different from the specified activity, prior to exposing them to mutagenesis.

17. The process of claim 16 which comprises prescreening said clones for the expression of a protein of interest.

18. A process for obtaining a protein having a specified protein activity, which process comprises:
screening, for the specified activity, a library of clones containing nucleic acid from a pool of nucleic acid populations which have been exposed to mutagenesis in an attempt to produce in the library of clones nucleic acid encoding a protein having one or more desired characteristics which can be the same or different from the specified protein activity.

19. The process of claim 18 which further comprises, prior to said mutagenesis, selectively recovering from the heterogeneous nucleic acid population nucleic acid which comprises nucleic acid sequences

coding for at least one common protein characteristic, which can be the same or different from the specified protein activity.

20. The process of claim 19 wherein the at least one common characteristic is at least one common enzyme activity.

21. The process of claim 20 wherein recovering the nucleic acid preparation comprises contacting the nucleic acid population with a specific binding partner for at least a portion of the coding sequences.

22. The process of claim 21 wherein the specific binding partner is a solid phase bound hybridization probe.

23. The process of claim 22 which comprises recovering nucleic acid from clones containing nucleic acid from the heterogeneous nucleic acid population which exhibit the class of enzyme activity.

24. The process of claim 18 wherein the mutagenesis is site-specific or random mutagenesis.

25. A process for providing a thermostable enzyme having improved enzyme activities at lower temperatures, said enzyme being a member selected from the group consisting of an enzyme or a polynucleotide encoding said enzyme comprising:

- (a) subjecting to mutagenesis at least one enzyme which is stable at a temperature of at least 60°C; and
- (b) screening mutants produced in (a) for a mutated enzyme or polynucleotide encoding a mutated enzyme, which mutated enzyme is stable at a temperature of at least 60°C and which has an enzyme activity at a temperature at least 10° C below its optimal temperature range and which has activity greater than the enzyme of step (a).

26. A process in which a nucleic acid library derived from at least one microorganism is subjected to a selection procedure to select therefrom double-stranded nucleic acid which hybridizes to one or more probe nucleic acid sequences which is all or a portion of a nucleic acid sequence encoding a protein having the specified protein activity, which process comprises:

(a) contacting the double-stranded nucleic acid population with the nucleic acid probe bound to a ligand under conditions permissive of hybridization so as to produce a complex of probe and members of the nucleic acid population which hybridize thereto;


(b) separating the complexes from the unbound nucleic acid population;

(c) releasing from the probe the members of the population which had bound to the probe;

(d) introducing the double-stranded nucleic acid of (c) into a suitable host to form a library containing a plurality of clones containing the selected nucleic acid; and

(e) screening the library for the specified protein activity.


1 / 7



10 ng (lib. 17)
1 ng
100 pg
10 pg

FIG. 1A

a
b
c Gene specific primers
d (1:100 dilution)
e
f standards



1 pg (lib. 17)
100 fg
10 fg
1 fg

FIG. 1B

a
b
c Vector specific primers
d (1:1000 dilution)
e
f standards

Panned Unpanned





FIG. 2

2 / 7

FIG. 3A

Match with FIG. 3B 


1	ATG	CTA	CCA	GAA	GGC	TTT	CTC	TGG	GGC	GTG
1	Met	Leu	Pro	Glu	Gly	Phe	Leu	Trp	Gly	Val
61	GAC	AAG	CTC	AGG	AGG	AAC	ATT	GAT	CCG	AAC
21	Asp	Lys	Leu	Arg	Arg	Asn	Ile	Asp	Pro	Asn
121	TTC	AAC	ATA	AAG	AGG	GAA	CTC	GTC	AGC	GGC
41	Phe	Asn	Ile	Lys	Arg	Glu	Leu	Val	Ser	Gly
181	GAA	CTT	TAC	GAG	AAG	GAT	CAC	CCC	CTC	GCC
61	Glu	Leu	Tyr	Glu	Lys	Asp	His	Pro	Leu	Ala
241	GGA	ATA	GAG	TGG	AGC	AGG	ATC	TTT	CCC	TGG
81	Gly	Ile	Glu	Trp	Ser	Arg	Ile	Phe	Pro	Trp
301	CGG	GAC	AGC	TAC	GGA	CTC	GTG	AAG	GAC	GTC
101	Arg	Asp	Ser	Tyr	Gly	Leu	Val	Lys	Asp	Val
361	GAC	GAG	ATA	GCG	AAT	CAT	CAG	GAG	ATA	GCC
121	Asp	Glu	Ile	Ala	Asn	His	Gln	Glu	Ile	Ala
421	GAG	CTG	GGC	TTC	AAG	GTC	ATC	GTG	AAC	CTC
141	Glu	Leu	Gly	Phe	Lys	Val	Ile	Val	Asn	Leu
481	GAT	CCG	ATA	ATC	GCG	AGG	GAG	AAG	GCC	CTC
161	Asp	Pro	Ile	Ile	Ala	Arg	Glu	Lys	Ala	Leu
541	GAG	AGC	GTG	GTG	GAG	TTC	GCC	AAG	TAC	GCG
181	Glu	Ser	Val	Val	Glu	Phe	Ala	Lys	Tyr	Ala

Match with FIG. 3 c

SUBSTITUTE SHEET (RULE 26)

3 / 7

FIG. 3B


 Match with FIG. 3 A

TCC	CAG	TCC	GGC	TTT	CAG	TTC	GAG	ATG	GGC	60
Ser	Gln	Ser	Gly	Phe	Gln	Phe	Glu	Met	Gly	20
ACA	GAC	TGG	TGG	AAG	TGG	GTC	AGG	GAT	CCC	120
Thr	Asp	Trp	Trp	Lys	Trp	Val	Arg	Asp	Pro	40
GAC	CTG	CCC	GAG	GAG	GGG	ATA	AAC	AAC	TAC	180
Asp	Leu	Pro	Glu	Glu	Gly	Ile	Asn	Asn	Tyr	60
AGA	GAC	CTC	GGT	CTG	AAC	GTT	TAC	AGG	ATT	240
Arg	Asp	Leu	Gly	Leu	Asn	Val	Tyr	Arg	Ile	80
CCA	ACG	TGG	TTT	GTG	GAG	GTT	GAC	GTT	GAA	300
Pro	Thr	Trp	Phe	Val	Glu	Val	Asp	Val	Glu	100
AAA	ATC	GAT	AAA	GAC	ACG	CTC	GAA	GAG	CTC	360
Lys	Ile	Asp	Lys	Asp	Thr	Leu	Glu	Glu	Leu	120
TAC	TAC	CGC	CGC	GTT	ATA	GAG	CAC	CTC	AGG	420
Tyr	Tyr	Arg	Arg	Val	Ile	Glu	His	Leu	Arg	140
AAC	CAC	TTC	ACG	CTC	CCC	CTC	TGG	CTT	CAC	480
Asn	His	Phe	Thr	Leu	Pro	Leu	Trp	Leu	His	160
ACC	AAC	GGT	AGG	ATT	GGC	TGG	GTC	GGG	CAG	540
Thr	Asn	Gly	Arg	Ile	Gly	Trp	Val	Gly	Gln	180
GCG	TAC	ATC	GCG	AAC	GCA	CTC	GGG	GAC	CTC	600
Ala	Tyr	Ile	Ala	Asn	Ala	Leu	Gly	Asp	Leu	200

MATCH WITH FIG. 3D

Match with FIG. 3 A 4 / 7

FIG. 3C

Match with FIG. 3D

601	GTT	GAT	ATG	TGG	AGC	ACC	TTC	AAC	GAR	CCG
201	Val	Asp	Met	Trp	Ser	Thr	Phe	Asn	Glu	Pro
661	CCC	TAC	TCC	GGY	TTT	CCN	CCG	GGG	GTT	ATG
221	Pro	Tyr	Ser	Gly	Phe	Pro	Pro	Gly	Val	Met
721	AAC	ATG	ATA	AAC	GCC	CAC	GCA	CTG	GCC	TAC
241	Asn	Met	Ile	Asn	Ala	His	Ala	Leu	Ala	Tyr
781	GCC	GAT	AAG	GAT	TCC	CGC	TCC	GAG	GCC	GAG
261	Ala	Asp	Lys	Asp	Ser	Arg	Ser	Glu	Ala	Glu
841	NCC	TAT	CCA	NAC	GAC	TCC	AAC	GAC	CCN	AAG
281	Xxx	Tyr	Pro	Xxx	Asp	Ser	Asn	Asp	Pro	Lys
901	TTC	CAC	AGC	GGG	CTC	TTC	TTC	GAC	GCA	ATC
301	Phe	His	Ser	Gly	Leu	Phe	Phe	Asp	Ala	Ile
961	GGT	GAG	ACC	TTC	GTC	AAA	GTT	CGG	CAT	CTC
321	Gly	Glu	Thr	Phe	Val	Lys	Val	Arg	His	Leu
1021	TAC	ACG	AGA	GAA	GTC	GTC	AGG	TAT	TCG	GAG
341	Tyr	Thr	Arg	Glu	Val	Val	Arg	Tyr	Ser	Glu
1081	TTC	CGG	GGA	GTT	CAC	AAC	TAC	GGT	TAC	GCC
361	Phe	Arg	Gly	Val	His	Asn	Tyr	Gly	Tyr	Ala
1141	AGG	CCC	GTA	AGC	GAC	ATC	GGC	TGG	GAG	ATC
381	Arg	Pro	Val	Ser	Asp	Ile	Gly	Trp	Glu	Ile

Match with FIG. 3E

5 / 7

Match with FIG. 3B



Match with FIG. 3C

FIG. 3D

ATG	GTC	GTT	GTG	GAN	CTC	GGT	TAC	CTC	GCG	660
Met	Val	Val	Val	Xxx	Leu	Gly	Tyr	Leu	Ala	220
AAC	CCC	GAG	GCG	GMN	AAN	CTG	GCA	ATC	CTC	720
Asn	Pro	Glu	Ala	Xxx	Xxx	Leu	Ala	Ile	Leu	240
AAG	ATG	ATA	AAG	AAG	TTC	GAC	AGG	GTA	AAG	780
Lys	Met	Ile	Lys	Lys	Phe	Asp	Arg	Val	Lys	260
GTC	GGG	ATA	ATC	TAC	AAC	AAC	ATA	GGC	GTT	840
Val	Gly	Ile	Ile	Tyr	Asn	Asn	Ile	Gly	Val	280
GAC	GTG	AAA	NCT	NCA	GAA	AAC	GAC	AAC	TAC	900
Asp	Val	Lys	Xxx	Xxx	Glu	Asn	Asp	Asn	Tyr	300
CAC	AAG	GGC	AAG	CTC	AAC	ATC	GAG	TTC	GAC	960
His	Lys	Gly	Lys	Leu	Asn	Ile	Glu	Phe	Asp	320
AGG	GGG	AAC	GAC	TGG	ATA	GGC	GTT	AAC	TAC	1020
Arg	Gly	Asn	Asp	Trp	Ile	Gly	Val	Asn	Tyr	340
CCC	AAG	TTC	CCG	AGC	ATA	CCC	CTG	ATA	TCC	1080
Pro	Lys	Phe	Pro	Ser	Ile	Pro	Leu	Ile	Ser	360
TGC	AGG	CCC	GGG	AGT	TCT	TCC	GCC	GAC	GGA	1140
Cys	Arg	Pro	Gly	Ser	Ser	Ser	Ala	Asp	Gly	380
TAT	CCG	GAG	GGG	ATC	TAC	GAC	TCG	ATA	AGA	1200
Tyr	Pro	Glu	Gly	Ile	Tyr	Asp	Ser	Ile	Arg	400

MATCH WITH FIG. 3C 6 / 7

FIG. 3E

MATCH WITH FIG. 3F

1201 GAG GCC AAC AAA TAC GGG GTC CCG GTT TAC
 401 Glu Ala Asn Lys Tyr Gly Val Pro Val Tyr

1261 GAC ACC CTG CGG CCG TAC TAC CTC GCG AGC
 421 Asp Thr Leu Arg Pro Tyr Tyr Leu Ala Ser

1321 GCG GGT TAC GAC GTC AGG GGC TAC CTC TAC
 441 Ala Gly Tyr Asp Val Arg Gly Tyr Leu Tyr

1381 CTC GGT TTC AGG ATG AGG TTC GGC CTC TAT
 461 Leu Gly Phe Arg Met Arg Phe Gly Leu Tyr

1441 CCG CGG GAG GAA AGC GTA AAG GTT TAT AGG
 481 Pro Arg Glu Glu Ser Val Lys Val Tyr Arg

1501 GAA ATC CGG GAG AAG TTC GGA CTT GGG TGA
 501 Glu Ile Arg Glu Lys Phe Gly Leu Gly End


FIG. 3A	FIG. 3B
FIG. 3C	FIG. 3D
FIG. 3E	FIG. 3F

FIG. 3

7 / 7

Match with FIG. 3D

FIG. 3F


 Match with FIG. 3E

GTC	ACC	GAA	AAC	GGA	ATA	GCC	GAT	TCA	ACT	1260
Val	Thr	Glu	Asn	Gly	Ile	Ala	Asp	Ser	Thr	420
CAT	GTA	GCG	AAG	ATT	GAG	GAG	GCG	TAC	GAG	1320
His	Val	Ala	Lys	Ile	Glu	Glu	Ala	Tyr	Glu	440
TGG	GCG	CTG	ACC	GAC	AAC	TAC	GAG	TGG	GCC	1380
Trp	Ala	Leu	Thr	Asp	Asn	Tyr	Glu	Trp	Ala	460
AAA	GTG	GAT	CTC	ATA	ACC	AAG	GAG	AGA	ACA	1440
Lys	Val	Asp	Leu	Ile	Thr	Lys	Glu	Arg	Thr	480
GGC	ATC	GTG	GAG	AAC	AAC	GGA	GTG	AGC	AAG	1500
Gly	Ile	Val	Glu	Asn	Asn	Gly	Val	Ser	Lys	500

1530

510

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/19457

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12N 9/00

US CL : 435/183

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/183

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN: Medline, Caplus, Biosis, Embase and WPIDS


APS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ----- Y	OSUNA et al. Combinatorial mutagenesis of three major groove-contacting residues of EcoRI: single and double amino acid replacements retaining methyltransferase-sensitive activity. Gene. 1991, Vol. 106, pages 7-12, see the abstract.	6-11, 13-21 and 24-26 ----- 1-5, 12, 22, and 23
X ----- Y	DUBE et al. Artificial mutants generated by the insertion of random oligonucleotides into the putative nucleoside binding site of the HSV-1 thymidine kinase gene. Biochemistry. 1991, Vol. 30, pages 11760-11767, see abstract.	6-11, 13-21 and 24-26 ----- 1-5, 12, 22 and 23

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be of particular relevance	* X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E* earlier document published on or after the international filing date	* Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* A* document member of the same patent family
* O* document referring to an oral disclosure, use, exhibition or other means	
* P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 24 JANUARY 1997	Date of mailing of the international search report 05 MAR 1997
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer  NASHAAT T. NASHED Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/19457

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — Y	BURIONI et al. Engineering human monoclonal antibody fragments: A recombinant enzyme-linked Fab. Microbiologica. April 1995, Vol. 18, pages 127-133, see abstract.	6-11, 13-21 and 24-26 ----- 1-5, 12, 22 and 23
Y	BORREGO et al. Combinatorial libraries by cassette mutagenesis. Nucleic Acid Research. 1995, Vol. 23, No. 10, pages 1834-1835, see page 1834, left column, first paragraph.	1-26

